Prime Medicine, Inc.

PRME

Offer Price Offer Size 3-Year Outlook Volatility 1st Day Turnover
$17.00 10,300,000 Positive High 26.99%

Offering Team

Deal Managers

  • J P Morgan Chase
  • Goldman Sachs
  • Morgan Stanley

Lawyers

  • Goodwin Procter LLP

Auditors

  • PricewaterhouseCoopers LLP, or PwC

Pre-IPO Investors

Investors

  • Google Ventures
  • Intel Ventures
  • Patricoff Ventures
  • Kleiner Perkins

Pre-IPO Holdings(%)

  • 30
  • 20
  • 05
  • 18

Deal Highlights

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as More

Deal Tracker

Investors

Filing

19 Oct, 2022

Offer

20 Oct, 2022

Look Ahead

Lock Up Expiry

20 Apr, 2023

Earning

Nov 1, 2018

IPO Terms

Offer Price $17.00
Offer Size 10M

Market Sentiments

Stock Price